NCT06718309View on ClinicalTrials.gov

Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2029

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Chemotherapy

Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin. The chemotherapy treatment lasts 3 cycles.

DRUG

Immunotherapy

Investigators choose PD-1 or PD-L1 according to drug indication and the immunotherapy lasts 3 cycles preoperatively and 1 year after surgery.

PROCEDURE

Radical resection of lung cancer

Radical resection of lung cancer with lymph node dissection

RADIATION

SBRT

SBRT for primary lung lesion 8Gy\*3F after first cycle of chemoimmunotherapy

Trial Locations (1)

310002

RECRUITING

Department of Thoracic Oncology, Hangzhou Cancer Hospital, Hangzhou

All Listed Sponsors
lead

First People's Hospital of Hangzhou

OTHER